Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Driscoll

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trialsJames J Driscoll, Oliver Rixe
Archives of Pathology & Laboratory Medicine|May 6, 2010
Hidradenocarcinomas: a brief review and future directionsSteven Gauerke, James J Driscoll
Cancer Metastasis Reviews|October 21, 2017
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitorsJames J Driscoll, Magen Brailey
Frontiers in Medicine|November 14, 2024
A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosisSindhuja Senigarapu, James J Driscoll
Targeted Oncology|December 3, 2010
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategyJames J Driscoll, Roopa Dechowdhury
Oncotarget|May 28, 2016
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibEhsan Malek, James J Driscoll
Cancer Letters|July 12, 2012
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implicationsJames J Driscoll, Roopa De Chowdhury
Seminars in Hematology|June 26, 2012
Targeting the ubiquitin+proteasome system in solid tumorsJames J Driscoll, E Steve Woodle
International Journal of Molecular Sciences|June 13, 2014
MicroRNAs in brain metastases: potential role as diagnostics and therapeuticsSamer Alsidawi, Ehsan Malek, James J Driscoll
Oncotarget|October 3, 2014
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancerEhsan Malek, Sajjeev Jagannathan, James J Driscoll
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trialsJames J Driscoll, Oliver Rixe
Archives of Pathology & Laboratory Medicine|May 6, 2010
Hidradenocarcinomas: a brief review and future directionsSteven Gauerke, James J Driscoll
Cancer Metastasis Reviews|October 21, 2017
Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitorsJames J Driscoll, Magen Brailey
Frontiers in Medicine|November 14, 2024
A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosisSindhuja Senigarapu, James J Driscoll
Targeted Oncology|December 3, 2010
Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategyJames J Driscoll, Roopa Dechowdhury
Oncotarget|May 28, 2016
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomibEhsan Malek, James J Driscoll
Cancer Letters|July 12, 2012
Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implicationsJames J Driscoll, Roopa De Chowdhury
Seminars in Hematology|June 26, 2012
Targeting the ubiquitin+proteasome system in solid tumorsJames J Driscoll, E Steve Woodle
International Journal of Molecular Sciences|June 13, 2014
MicroRNAs in brain metastases: potential role as diagnostics and therapeuticsSamer Alsidawi, Ehsan Malek, James J Driscoll
Oncotarget|October 3, 2014
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancerEhsan Malek, Sajjeev Jagannathan, James J Driscoll
Pageof 5